Suggested remit: To appraise the clinical and cost effectiveness of histamine dihydrochloride with interleukin-2 within its marketing authorisation for maintenance treatment of acute myeloid leukaemia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 1627
Provisional Schedule
- Committee meeting: 1:
- 04 February 2026
- Expected publication:
- 22 April 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Brancaster Pharma
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Bayer (sorafenib) (confidentiality agreement signed, participating)
- Pfizer (cytarabine) (confidentiality agreement signed, participating)
- Accord Healthcare (cytarabine, sorafenib) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (azacitidine) (confidentiality agreement not signed, not participating)
- Daiichi Sankyo (quizartinib) (confidentiality agreement not signed, not participating)
- Hospira UK (cytarabine) (confidentiality agreement not signed, not participating)
- Jazz Pharmaceuticals (cytarabine) (confidentiality agreement not signed, not participating)
- Napp Pharmaceuticals (cytarabine) (confidentiality agreement not signed, not participating)
- Novartis Pharmaceuticals (midostaurin) (confidentiality agreement not signed, not participating)
- Sandoz (sorafenib) (confidentiality agreement not signed, not participating)
- Teva UK (sorafenib) (confidentiality agreement not signed, not participating)
- Thornton & Ross (sorafenib) (confidentiality agreement not signed, not participating)
- Zentiva UK (sorafenib) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 | Invitation to participate |
| 22 May 2025 - 20 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1627 |
| 22 May 2025 | In progress. Scoping commencing |
| 06 February 2025 | As you will be aware The Department for Health & Social Care has asked NICE to conduct an appraisal of Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] Please note that following on from a request received from the company this appraisal have been scheduled into the work programme and the appraisal is now anticipated to begin during early July 2025 when we will write to you about how you can get involved. |
| 26 June 2020 | Suspended: The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets histamine dihydrochloride have ceased to engage with NICE regarding this appraisal. NICE have therefore taken the decision to suspend this topic from the work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please contact the project manager for this appraisal Emily Richards on (44 (0)161 413 4070 or via email on [email protected]) |
| 26 June 2020 | Suspended. _ |
For further information on our processes and methods, please see our CHTE processes and methods manual